These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 2064730)

  • 21. Nocturnal melatonin secretion and its modification by treatment in patients with sleep disorders.
    Rodenbeck A; Huether G; Rüther E; Hajak G
    Adv Exp Med Biol; 1999; 467():89-93. PubMed ID: 10721043
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of levodopa with carbidopa or benserazide in parkinsonism.
    Greenacre JK; Coxon A; Petrie A; Reid JL
    Lancet; 1976 Aug; 2(7982):381-4. PubMed ID: 73849
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term treatment of Parkinson's disease with L-Dopa and Dopa-decarboxylase inhibitor: therapeutic results and side effects.
    Battistin L; Meneghetti G; Rigotti S; Saia A
    Acta Neurol Scand; 1978 Feb; 57(2):186-92. PubMed ID: 347868
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A sustained-release formulation of L-dopa (Madopar HBS) in the treatment of nocturnal and early-morning disabilities in Parkinson's disease.
    Lees AJ
    Eur Neurol; 1987; 27 Suppl 1():126-34. PubMed ID: 3428306
    [TBL] [Abstract][Full Text] [Related]  

  • 25. L-dopa plus dopa-decarboxylase inhibitor. Sleep organization in Parkinson's syndrome before and after treatment.
    Bergonzi P; Chiurulla C; Gambi D; Mennuni G; Pinto F
    Acta Neurol Belg; 1975; 75(1):5-10. PubMed ID: 1202895
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetic-pharmacodynamic modeling of levodopa in patients with advanced Parkinson disease.
    Adamiak U; Kaldonska M; Klodowska-Duda G; Wyska E; Safranow K; Bialecka M; Gawronska-Szklarz B
    Clin Neuropharmacol; 2010 May; 33(3):135-41. PubMed ID: 20216409
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mortality among Parkinson patients treated with L-dopa combined with a decarboxylase inhibitor.
    Zumstein H; Siegfried J
    Eur Neurol; 1976; 14(5):321-8. PubMed ID: 949985
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Does O-methyl-dopa play a role in levodopa-induced dyskinesias?
    Feuerstein C; Tanche M; Serre F; Gavend M; Pellat J; Perret J
    Acta Neurol Scand; 1977 Jul; 56(1):79-82. PubMed ID: 878846
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Gastroretentive carbidopa/levodopa, DM-1992, for the treatment of advanced Parkinson's disease.
    Verhagen Metman L; Stover N; Chen C; Cowles VE; Sweeney M
    Mov Disord; 2015 Aug; 30(9):1222-8. PubMed ID: 25847690
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Decarboxylase inhibitors combined with L-dopa in the treatment of Parkinson's disease].
    Rondot P
    Rev Prat; 1974 Mar; 24(15):1211-2, 1215-6, 1219. PubMed ID: 4416964
    [No Abstract]   [Full Text] [Related]  

  • 31. Effect of dopamine agonist (Lergotrile mesylate) therapy on twenty-four hour secretion of prolactin in treated Parkinson's disease.
    Bell RD; Carruth A; Rosenberg RN; Boyar RM
    J Clin Endocrinol Metab; 1978 Oct; 47(4):807-11. PubMed ID: 45469
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [The L-dopa test in Parkinson's disease].
    Esteguy M; Bonnet AM; Kefalos J; Lhermitte F; Agid Y
    Rev Neurol (Paris); 1985; 141(5):413-5. PubMed ID: 4048732
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Aging and the circadian rhythm of melatonin: a cross-sectional study of Chinese subjects 30-110 yr of age.
    Zhao ZY; Xie Y; Fu YR; Bogdan A; Touitou Y
    Chronobiol Int; 2002 Nov; 19(6):1171-82. PubMed ID: 12511033
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Treatment of Parkinson's disease with levodopa and a dopa decarboxylase inhibitor].
    Londoõ R
    Neurol Neurocir Psiquiatr; 1976; 17(4):293-300. PubMed ID: 1018729
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of melatonin on sleep disorders in a monkey model of Parkinson's disease.
    Belaid H; Adrien J; Karachi C; Hirsch EC; François C
    Sleep Med; 2015 Oct; 16(10):1245-51. PubMed ID: 26429753
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Parkinson's disease as a neuroendocrine disorder of circadian function: dopamine-melatonin imbalance and the visual system in the genesis and progression of the degenerative process.
    Willis GL
    Rev Neurosci; 2008; 19(4-5):245-316. PubMed ID: 19145986
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The circadian rhythm of melatonin in hypothyroidism and hyperthyroidism.
    Soszyński P; Zgliczyński S; Pucilowska J
    Acta Endocrinol (Copenh); 1988 Oct; 119(2):240-4. PubMed ID: 3176816
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Melatonin rhythm observed throughout a three-cycle bright-light stimulus designed to reset the human circadian pacemaker.
    Shanahan TL; Kronauer RE; Duffy JF; Williams GH; Czeisler CA
    J Biol Rhythms; 1999 Jun; 14(3):237-53. PubMed ID: 10452336
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term Levodopa Treatment Accelerates the Circadian Rhythm Dysfunction in a 6-hydroxydopamine Rat Model of Parkinson's Disease.
    Li SY; Wang YL; Liu WW; Lyu DJ; Wang F; Mao CJ; Yang YP; Hu LF; Liu CF
    Chin Med J (Engl); 2017 May; 130(9):1085-1092. PubMed ID: 28469105
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Combined treatment of Parkinsonism with L-dopa and peripheral dopa decarboxylase inhibitors--clinical course of 13 cases and levels of serum/dopa and dopamine].
    Mizuno Y; Yoshida M; Obayashi T; Ueki A
    Rinsho Shinkeigaku; 1976 Jul; 16(7):511-9. PubMed ID: 986921
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.